New oral cholesterol pill enlicitide reduces LDL by 60%, matching injectable treatments

A large clinical trial has found that enlicitide, taken as an oral pill, reduces LDL cholesterol by approximately 60%. That number puts it in the same range as injectable PCSK9 inhibitors like evolocumab and alirocumab, which are currently among the most effective cholesterol-lowering therapies available but require self-injection every two to four weeks. The clinical significance of matching that level of LDL reduction with a pill rather than an injection is straightforward: more patients will actually take it.

Adherence to injectable cholesterol therapy is a persistent problem in cardiology. A 2021 analysis published in the Journal of the American Heart Association found that only 41% of patients prescribed PCSK9 inhibitors were still taking them at twelve months, compared to roughly 70% adherence rates for oral statins. The barrier is partly the injection itself, partly the frequency, and partly the requirement for refrigerated storage in some formulations. Enlicitide eliminates all three of those barriers at once.

How enlicitide works and why it is different from statins

Statins reduce LDL by inhibiting an enzyme called HMG-CoA reductase, which the liver uses to produce cholesterol. They have been the dominant oral cholesterol treatment for four decades and can reduce LDL by 30% to 55% depending on dose and individual response. Enlicitide works through a different mechanism. It inhibits PCSK9, a protein that breaks down LDL receptors on liver cells. When PCSK9 is blocked, liver cells retain more LDL receptors, which pull more LDL out of the bloodstream. The injectable PCSK9 inhibitors use antibodies to achieve this. Enlicitide achieves the same inhibition through a small molecule that survives oral delivery.

Getting a PCSK9 inhibitor to work as an oral drug has been a significant pharmaceutical chemistry challenge. Antibody-based drugs are proteins that get broken down in the digestive system before they can reach circulation. Enlicitide is a small molecule inhibitor, which means it can pass through the gut lining intact. Developing small molecules that bind PCSK9 with enough specificity and affinity to produce meaningful LDL reductions has taken more than a decade of research across multiple companies.

What the clinical trial actually measured

The Phase 3 trial enrolled patients who had documented cardiovascular disease or were at high cardiovascular risk and who had LDL levels above guideline targets despite maximally tolerated statin therapy. That patient population is precisely the group where injectable PCSK9 inhibitors are currently indicated. The trial ran for 52 weeks, measuring LDL reduction as the primary endpoint alongside cardiovascular events, liver enzyme levels, and muscle-related adverse events as secondary endpoints.

The 60% LDL reduction was measured against placebo in patients who continued their background statin therapy. The trial also included a comparator arm against a standard-dose statin, where enlicitide added an additional 38% LDL reduction on top of the statin's effect. The safety profile showed no significant increase in liver enzyme elevations or muscle symptoms compared to placebo, which addresses the two most common concerns that physicians raise about combining cholesterol-lowering agents.

Who stands to benefit most from an oral option

The patients most likely to benefit are those with familial hypercholesterolemia, a genetic condition affecting approximately 1 in 250 people worldwide that causes very high LDL levels from birth. Many of these patients cannot get LDL to guideline targets with statins alone and currently require injectable PCSK9 inhibitors. There are an estimated 31 million people with familial hypercholesterolemia globally, but only about 10% are diagnosed and receiving appropriate treatment, partly because of how difficult high-intensity therapy is to sustain long term.

Secondary prevention patients, those who have already had a heart attack or stroke and need to keep LDL as low as possible to prevent recurrence, are the other primary target group. Current American College of Cardiology guidelines recommend LDL below 55 mg/dL for very high-risk patients. Many patients cannot reach that target with statins alone, and the switch to or addition of an injectable drug involves a conversation about injection technique, storage, and ongoing out-of-pocket costs that deters some patients and physicians alike.

FDA review timeline and what comes next

The trial results were submitted to the FDA in February 2026. The agency has assigned enlicitide a Priority Review designation, which sets a six-month review timeline rather than the standard ten months. That puts a potential approval decision in August 2026 if the review proceeds without requests for additional data. The manufacturer has also filed for regulatory review in the European Union and the United Kingdom, with decisions expected in early 2027.

Pricing will be a significant factor in how widely enlicitide gets used. Injectable PCSK9 inhibitors launched at list prices around $14,000 per year in the United States, which led to widespread insurance coverage restrictions that limited prescribing to the highest-risk patients. The manufacturer of enlicitide has not disclosed a target price, but cardiology advocacy groups have publicly called for pricing in line with generic statins to maximize the public health impact of the 60% LDL reduction the trial demonstrated.